Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.
Hi, everyone, Tony Sri from the Dana Farber Cancer Institute. Um have the chance to present biomarker analysis in patients with advanced kidney cancer. From the phase three clinical trial by the name, clear, clear is a front line trial that established in kidney cancer. The combination of embolism of the PD one inhibited and lym patin tender. The study led to the approval of that combination based on progression free and overall survival benefits. But um we presented during so 24 in Chicago, the first biomarker assessment looking at PDL one, a gene alteration and a gene expression uh studies in that study, we found that PDL one expression by immuno histochemistry does not associate with response to pembrolizumab VT. In addition, when we looked at the top gene mutated VHL PV RM one B one and others in kidney cancer and whether they could predict um any response from pembrolizumab and lymph fin, we did not find that. And finally, uh the gene expression profile and the clusters that are established in kidney cancer. Um You know, when we looked at them, uh a con to show that the Lenvatinib and pembrolizumab combination remains superior to single agent, uh vegf thyroxin kinase inhibitors. So they do not predict uh efficacy. Again, that's the first biomarker analysis from clear.
